An overview of satavaptan: a selective V2 receptor antagonist

Author： Farah Jareer Daifallah Suleiman Zmily Hammam Ghali Jalal K

ISSN： 1475-0708

Source： Therapy, Vol.7, Iss.4, 2010-07, pp. : 409-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erythrocyte-protective effect of sarpogrelate hydrochloride (Anplag^®), a selective 5-HT₂ receptor antagonist: an in vitro study

By Nakamura Ken Kawahito Koji

Journal of Artificial Organs, Vol. 13, Iss. 3, 2010-09 ,pp. : 178-181

Springer Publishing Company

Access to resources Recommend Favorite

Darifenacin: a selective M₃ muscarinic receptor antagonist for the treatment of overactive bladder

By Smith Phillip P Lai H Henry Appell Rodney A

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 723-732

Future Medicine

Access to resources Recommend Favorite

The effects of sigma (σ1) receptor‐selective ligands on muscarinic receptor antagonist‐induced cognitive deficits in mice

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 10, 2015-05 ,pp. : 2519-2531

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2‐receptor antagonist

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 9, 2010-09 ,pp. : 1493-1497

John Wiley & Sons Inc

Access to resources Recommend Favorite

LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles

CLINICAL AND TRANSLATIONAL SCIENCE (ELECTRONIC), Vol. 11, Iss. 1, 2018-01 ,pp. : 46-53

John Wiley & Sons Inc

Access to resources Recommend Favorite